Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2016 Jan 1.
Published in final edited form as: Reprod Toxicol. 2014 Nov 25;51:31–39. doi: 10.1016/j.reprotox.2014.11.008

Stage-specific signaling pathways during murine testis development and spermatogenesis: a pathway-based analysis to quantify developmental dynamics

Susanna H Wegner 1, Xiaozhong Yu 1,*, Sara Pacheco Shubin 1, William C Griffith 1, Elaine M Faustman 1
PMCID: PMC4425996  NIHMSID: NIHMS651672  PMID: 25463528

Abstract

Shifting the field of developmental toxicology towards evaluation of pathway perturbation requires a quantitative definition of normal developmental dynamics. This project examined a publicly available dataset to quantify pathway dynamics during testicular development and spermatogenesis and anchor toxicant-perturbed pathways within the context of normal development. Genes significantly changed throughout testis development in mice were clustered by their direction of change using K-means clustering. Gene Ontology terms enriched among each cluster were identified using MAPPfinder. Temporal pathway dynamics of enriched terms were quantified based on average expression intensity for all genes associated with a given term. This analysis captured processes that drive development, including the peak in steroidogenesis known to occur around gestational day 16.5 and the increase in meiosis and spermatogenesis-related pathways during the first wave of spermatogenesis. Our analysis quantifies dynamics of pathways vulnerable to toxicants and provides a framework for quantifying perturbation of these pathways.

Keywords: testicular development, spermatogenesis, quantitative pathway analysis

Introduction

Increasing rates of reproductive disorders that have origins in early reproductive development demonstrate the need for methods to characterize and quantify perturbations of developmental processes in gonadal development and spermatogenesis. For example, there is mounting evidence for a consistent decline in semen quality in recent decades, accompanied by an increasing prevalence of male reproductive disorders, including hypospadias, undescended testes, and testicular cancer [16]. All of these adverse reproductive health outcomes are manifestations of testicular dysgenesis syndrome (TDS), a set of conditions believed to have common origins during early gonadal development [7]. Early testicular development and spermatogenesis are very sensitive processes that depend on a series of precisely timed steps regulated by hormonal cues and germ cell microenvironments [8, 9]. These processes in male reproductive development are therefore particularly vulnerable to perturbation by genetic and environmental factors [10, 11]. Indeed, the recent increase in TDS related conditions has been hypothesized to be a result of environmental factors that can influence early male reproductive development, such as exposure to endocrine disrupting chemicals [7].

Exploration of the complex interaction of environmental and genetic factors underlying reproductive disorders requires a systems-based framework for characterizing normal and perturbed pathway dynamics during critical windows of male reproductive development. The field of toxicology is increasingly shifting towards characterization of pathway perturbation as a sensitive indicator of toxicity [12]. A quantitative framework for measuring shifts from normal pathway dynamics would facilitate quantification of pathway perturbation by toxicants. Furthermore, incorporation of in vitro models into chemical screening, underscores the need to anchor pathway dynamics captured in these in vitro models to pathway dynamics driving in vivo development. The first step in being able to place pathway perturbation measured in vivo and in vitro within the context of normal development is to define normal pathway dynamics in vivo in an easily translatable, quantitative framework.

Fortunately, much of the data needed to provide this baseline characterization of normal developmental dynamics is available in publicly available datasets. Microarray-based high-throughput gene expression analysis has proven to be an effective method for studying the changes in gene expression associated with the growth and development of mammalian tissues [13, 14]. Many of the genetic drivers of male reproductive development have been characterized through mouse knockout models [15, 16] and global gene expression analysis [1721]. The Griswold lab at Washington State University has employed microarray-based gene expression analysis to characterize dynamic changes in global gene expression patterns over the course of several particularly sensitive processes of male reproductive development in mice [17, 18]. The group identified genes with changing expression patterns throughout gonadal differentiation and development and the first wave of spermatogenesis [17, 18]. The gene expression profiles observed by Small et al reiterated the known functional activities of each cell type, and suggested the involvement of novel genes in the maturation of the testis and differentiation of germ cells. Their temporal microarray study provides a valuable resource for evaluating biological factors that influence testis maturation and spermatogenesis. However, as with all microarray data, the functional interpretation of such a vast set of genomic data presents a major challenge. In order to elucidate the biological consequences of these expression changes in single genes, gene expression data must be integrated with quantitative information on functional changes in whole gene networks and developmental signaling pathways over time.

Gene ontology (GO) analysis is a powerful tool for translating a vast amount of genomic data into a description of functional changes in gene networks and signaling pathways. The GO approach has been successfully combined with pathway analysis to generate an unbiased determination of the statistical significance of changes observed in pathways of interest [2225]. For example, previous GO analysis of testicular gene expression has successfully identified pathways that are significantly changed throughout murine spermatogenesis [26]. However, standard GO analysis results in a list of enriched pathways with no quantitative description of how these pathways are changed. In addition these approaches did not retain quantitative information on the expression of individual genes and are limited to the evaluation of only two experimental dimensions.

In order to address the need to quantify changes in pathway dynamics through time or in response to an environmental exposure, our lab developed the GO-Quant approach [27]. GO-Quant incorporates gene expression data with Gene Ontology analysis in MAPPfinder [22] to calculate the average intensity of expression of all significantly altered genes associated with a given GO term. This allows the quantitative evaluation of the dynamics of entire gene pathways along a third dimension, such as developmental stage or toxicant dose. We first applied this quantitative pathway-based approach in a published dose- and time-dependent genomic dataset [28] and found that our systematic approach quantitatively described the degree to which functional gene systems changed across dose or time course [27, 29]. We have subsequently used our quantitative pathway analysis for a genome-wide assessment of phthalate toxicity in an in vitro rat testis co-culture model [30] and for an assessment of time- and dose-dependent methylmercury toxicity in developing mouse embryos undergoing neurulation [31].

In the current study, we applied our established quantitative pathway-based approach to a publicly available dataset of murine male reproductive development [18] to quantify the dynamic functional changes in biological processes that characterize normal testicular development and the first wave of spermatogenesis in vivo. Through this analysis we demonstrate that our approach can quantitatively illustrate pathway dynamics throughout a complex developmental process in vivo, successfully capturing well characterized developmental milestones. The result provides a framework for quantifying perturbation of normal developmental pathways in vivo as well as anchoring emerging in vitro models of male reproductive development to in vivo pathway dynamics.

Materials and Methods

Gene Expression Data Set

For this analysis we obtained publically available temporal mouse genomic data during early testis development (gestational days (GD) 11.5, 12.5, 14.5, 16.5, and 18.5) and the first wave of spermatogenesis (postnatal days (PND) 0, 3, 6, 8, 10, 14, 18, 20, 30, 35, and 56). Gene expression intensity in testicular tissue at each timepoint was quantified using Affymetrix MGU74Av2, Bv2, and Cv2 arrays. Detailed methods of sample collection and microarray processing are available in the original papers [17, 18]. NCBI’s gene expression omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/) was used to retrieve the raw dataset.

Identification and Clustering of Significantly Changed Genes

Microarray analysis was conducted based on our established quantitative pathway-based approach as shown in Figure 1 [27]. Significantly changed probes were identified using BRB ArrayTools, developed by Dr. Richard Simon and the BRB ArrayTools Development Team. Data were normalized by gcRMA normalization and log2 transformed. In order to identify significantly changed probes, we conducted an ANOVA class comparison across timepoints. Genes that were significantly altered (p ≤ 0.001) across time were selected and K-means cluster analysis was used to group genes based on the similarity of their patterns of mean expression though time. Since there are generally two directions of gene expression changes at a certain time (either up-regulation or down-regulation within a specific gene category), the average of these two different directions of gene expression alteration would mask the degree of absolute change in a pathway. For pathway analysis, we therefore separated significantly changed genes into two groups with patterns of expression tending towards consistent up- or down-regulation across time based on K-means cluster analysis [32].

Figure 1. Microarray Analysis Pipeline for Quantification of Pathway Dynamics.

Figure 1

A) Summary of analysis pipeline B) Illustration of data analysis process. Starting with single gene expression in testis through time (Shima et al, 2004) we normalized data and identified significantly changed genes using BRB Arraytools software, clustered genes with significantly increasing or decreasing expression through time using Multiple Experiment Viewer software (MEV), then used GO Quant software to identify GO terms enriched among these clusters and average the expression of all significantly changed genes in that pathway to produce a quantitative summary of gene expression dynamics in each GO term through time.

Identification of Enriched GO terms

We applied MAPPfinder to identify enriched Gene Ontology (GO) terms at p ≤ 0.001 [33] in up- and down-regulated probes at each timepoint. Enriched GO terms were ranked by Z-score and permutation p-value [33]. As previously described, the Z-score, a statistical measure of significance for gene expression in a given group, was calculated by subtracting the number of genes expected to be randomly changed in a GO term from the observed number of changed genes in that GO term. This value was then divided by the standard deviation of the observed number of genes under a hypergeometric distribution. The equation is written out as

Zscore=(rn*(R/N))/((n*(R/N))(1(R/N))(1((n1)/(N1)))^1/2 (1)

where N is the total number of genes measured, R is the total number of genes meeting the criterion that the gene be significantly changed based on an F test at significant p <= 0.001 value, n is the total number of genes in each specific GO term, and r is the number of genes meeting the criterion in this specific GO term. Complete lists of GO terms enriched among significantly upor down-regulated genes are available as supplemental data (Supplemental Tables 1 and 2).

Quantification of Pathway Dynamics Throughout Development

To quantify the dynamic changes in GO terms through time, we used GO-Quant to link enriched GO terms to the expression values of all the significantly up- or down-regulated genes contained within the pathway. By incorporating gene expression data into the pathway analysis, we could compute the average intensity of expression among genes in each enriched GO term at each timepoint. These values at individual timepoints were then normalized to ‘average’ expression across time by subtracting the average expression intensity of genes in the GO term across all the timepoints. This yielded a log2 ratio of mean expression at each timepoint relative to the average mean expression across all timepoints. Plotting the log2 ratio for each GO term through time illustrates temporal pathway dynamics throughout development. GO terms included in the figures and tables presented here are the ten biological processes with the highest Z-scores that are relevant to each of the dominant categories selected.

Results

Our quantitative pathway analysis (summarized in Figure 1A) translates a vast amount of information on expression of single genes into a quantitative summary of temporal changes in activity across entire gene networks and biological processes described by GO terms (Figure 1B). Of the approximately 36,000 probes on the array, 9,599 probes were significantly changed through time. Significant genes were clustered into two groups based on their general expression trends using K-means clustering. This resulted in segregation of significantly changed genes into two sets: one set with overall upward trends in expression and another set with overall downward trends in expression. We then used MAPPFinder to identify GO terms describing biological processes that were enriched among each of these two gene clusters. We found 308 GO terms enriched among genes with downwards trends in expression and 112 GO terms enriched among genes with upward trends in expression. For each of these enriched GO terms, GO-Quant facilitated generation of a quantitative temporal summary of average gene expression dynamics at each timepoint among genes significantly changed in the pathway through time.

GO Terms Significantly Enriched Among Genes with Upward Trends in Expression

The GO terms most significantly over represented among genes with increased expression are dominated by terms associated with spermatogenesis and meiosis (Table 1). Indeed, 12 of the top 20 (60%) of significantly enriched GO terms ranked by Z-score are directly relevant to spermatogenesis or meiosis (Supplemental Table 1). Quantitative pathway analysis reveals that average gene expression in GO terms related to meiosis (Figure 2B) begins increasing around PND 3, slightly preceding the spermatogenesis and spermatid maturation signal. We see a dramatic increase in the average expression of genes in GO terms relating to spermatogenesis and spermatid development throughout testis development, capturing gene expression dynamics that are closely aligned in time with known developmental outcomes (Figure 2A). Average expression of genes involved in a host of GO terms relating to spermatid development and differentiation begin a gradual increase on PND 10 with the emergence of spermatocytes, increase around PND 20 when spermatids appear, and remain high through PND 56 as the first wave of spermatogenesis is completed and spermatozoa are produced. Simultaneously, average expression in GO terms associated with a panel of pathways related to ubiquitin mediated processes (Figure 2C) and epigenetic processes (Figure 2D) increases in parallel, with over a quarter of the genes associated with chromatin remodeling and ubiquitin cycle changing significantly through spermatogenesis.

Table 2.1.

GO Terms Enriched Among Genes With Significantly Increased Expression Through Time

GOID GO Name # Genes
in GO
% of
Present
Genes
Changed
% of
Genes
Present
on Array
Z-Score Parametric
p-value
Spermatogenesis and Sperm Maturation
48232 male gamete generation 194 53.3 70.6 11.935 4.0E-05
7283 spermatogenesis 194 53.3 70.6 11.935 4.0E-05
7276 gamete generation 278 41.8 66.2 9.601 5.1E-05
30317 sperm motility 15 75 106.7 6.427 3.7E-05
48515 spermatid differentiation 36 56.2 88.9 6.202 7.7E-05
7286 spermatid development 34 56.7 88.2 6.067 3.3E-05
1539
48240
ciliary or flagellar motility
sperm capacitation
6
5
100
100
66.7
60
4.574
3.961
1.7E-06
3.3E-05
Meiotic Cell Cycle
7127 meiosis I 32 63.2 59.4 5.597 1.9E-04
51327 M phase of meiotic cell cycle 76 37.7 69.7 4.309 1.5E-04
7126 meiosis 76 37.7 69.7 4.309 1.5E-04
51321 meiotic cell cycle 77 37 70.1 4.21 1.5E-04
7131 meiotic recombination 17 75 23.5 3.212 6.4E-06
7128 meiotic prophase I 4 60 125 2.677 1.0E-07
7130 synaptonemal complex assembly 6 60 83.3 2.677 1.1E-04
Ubiquitin Mediated Processes
6512 ubiquitin cycle 433 25.3 83.1 4.837 7.7E-05
6511 ubiquitin-dependent protein catabolic process 165 28.9 69.1 3.767 6.9E-05
19941 modification-dependent protein catabolic process 167 28.4 69.5 3.654 6.9E-05
43632 modification-dependent macromolecule catabolic process 167 28.4 69.5 3.654 6.9E-05
6464 protein modification process 1609 19.5 78.3 3.535 8.7E-05
Epigenetic Regulation
43687 post-translational protein modification 1375 19.1 79.1 2.895 8.5E-05
6338 chromatin remodeling 52 28.9 73.1 2.169 8.6E-05
31497 chromatin assembly 142 25.4 44.4 2.026 3.6E-05
6333 chromatin assembly or disassembly 180 23.6 49.4 1.945 7.0E-05

Figure 2. Quantified Pathway Dynamics of GO Terms that Significantly Increase Through Time.

Figure 2

GO terms enriched among genes with significantly increasing expression (p<0.001) through time were identified through MAPPfinder. Significantly enriched GO terms (p<0.001) were ranked by Z-score and dominant themes among these terms were identified as A) Spermatogenesis, B) Meiosis, C) Ubiquitin Mediated Processes, and D) Epigenetic Processes. Dynamic change in GO terms related to each dominant theme are plotted here as the ratio of average Log2 intensity of expression of all significantly changed genes at each timepoint in a GO term over Average Log2 intensity across all timepoints for that GO term. Corresponding stages of spermatogenesis, including spermatogonia (SPG), spermatocyte (SPC), spermatid (SPT), and spermatozoa (SPZ) are indicated along the X axis.

GO Terms Significantly Enriched Among Genes with Downward Trends in Expression

The dominant themes in GO terms enriched among genes with decreasing expression through time include developmental processes, metabolic processes, developmental signaling pathways, mitosis, and steroid regulation (Table 2). Quantitative pathway analysis illustrates dynamic changes in GO terms related to steroid regulation throughout testis development. For example, average gene expression in sterol metabolic and biosynthetic processes peak at GD 16.5, decrease before birth, and decrease further after spermatid development commences (Figure 3A). Several other catabolic and metabolic pathways, including lipid metabolism, follow a similar pattern of expression (Figure 3B).

Table 2.2.

GO Terms Enriched Among Genes With Significantly Decreased Expression Through Time

GOID GO Name # Genes
in GO
% of
Present
Genes
Changed
% of
Genes
Present
on Array
Z-Score Parametric
p-value
Steroid Regulation
16125 sterol metabolic process 73 44.1 80.8 2.997 7.3E-05
6694 steroid biosynthetic process 75 46.3 72 3.237 5.7E-05
6695 cholesterol biosynthetic process 25 55 80 2.846 4.1E-05
8203 cholesterol metabolic process 67 43.4 79.1 2.729 6.0E-05
16126 sterol biosynthetic process 31 50 83.9 2.67 7.4E-05
8202 steroid metabolic process 145 36.5 79.3 2.358 9.8E-05
Cellular Metabolism
8152 metabolic process 8113 28.8 76.1 4.835 1.3E-04
44238 primary metabolic process 7338 29 75.1 4.83 1.3E-04
43170 macromolecule metabolic process 6411 28.8 74.7 3.91 1.3E-04
44237 cellular metabolic process 7311 28.9 75.4 4.651 1.3E-04
9059 macromolecule biosynthetic process 899 34.8 65.5 4.476 1.5E-04
19538 protein metabolic process 3404 29.4 74 3.263 1.3E-04
44249 cellular biosynthetic process 646 33.1 74.9 3.156 1.4E-04
44255 cellular lipid metabolic process 542 33.2 81.2 3.063 1.4E-04
19320 hexose catabolic process 91 44.2 57.1 2.839 1.3E-04
46365 monosaccharide catabolic process 91 44.2 57.1 2.839 1.3E-04
Developmental Processes
32502 developmental process 3292 31.8 75.6 6.268 1.2E-04
32989 cellular structure morphogenesis 485 39.4 77.9 5.61 7.9E-05
902 cell morphogenesis 485 39.4 77.9 5.61 7.9E-05
9887 organ morphogenesis 457 39.2 82.1 5.49 8.6E-05
9790 embryonic development 362 39.2 94.5 5.229 6.1E-05
35295 tube development 128 46.9 100 5.146 5.3E-05
48731 system development 1704 32.5 74.9 4.824 1.0E-04
35239 tube morphogenesis 83 48.9 106 4.683 6.2E-05
48513 organ development 1345 32.2 76.4 4.077 1.0E-04
50793 regulation of developmental process 256 38.8 85.5 4.039 7.9E-05
Developmental Signaling Pathways
8593 regulation of Notch signaling pathway 5 100 80 3.304 2.0E-05
48013 ephrin receptor signaling pathway 3 100 133.3 3.304 4.2E-05
30509 BMP signaling pathway 26 57.1 80.8 3.139 1.5E-04
7266 Rho protein signal transduction 102 41.5 80.4 3.002 1.6E-04
43405 regulation of MAPK activity 77 44.4 70.1 2.929 9.7E-05
35023 regulation of Rho protein signal transduction 72 42.2 88.9 2.781 1.8E-04
7265 Ras protein signal transduction 172 37.4 71.5 2.66 1.7E-04
9966 regulation of signal transduction 411 32.1 78.8 2.171 1.6E-04
187 activation of MAPK activity 48 43.8 66.7 2.164 9.9E-05
7219 Notch signaling pathway 51 40.9 86.3 2.113 5.6E-05
Mitotic Cell Cycle
51301 cell division 218 42.9 90.8 5.155 1.7E-04
278 mitotic cell cycle 249 39.6 81.1 4.133 1.3E-04
7067 mitosis 168 41.7 85.7 4.043 1.4E-04
87 M phase of mitotic cell cycle 170 41.5 86.5 4.039 1.4E-04
8283 cell proliferation 648 35.3 63 3.925 9.8E-05
22402 cell cycle process 646 34.9 69.2 3.923 1.4E-04
7049 cell cycle 762 33.7 74.4 3.773 1.3E-04
6275 regulation of DNA replication 19 70 52.6 3.083 1.5E-04
51726 regulation of cell cycle 461 33.5 60.3 2.523 1.3E-04
74 regulation of progression through cell cycle 459 33.5 59.9 2.509 1.3E-04

Figure 3. Quantified Pathway Dynamics of GO terms that Significantly Decrease Through Time.

Figure 3

GO terms enriched among genes with significantly decreasing expression (p<0.001) through time were identified through MAPPfinder. Significantly enriched GO terms (p<0.001) were ranked by Z-score and dominant themes among these terms were identified as A) Steroid Regulation B) Cellular Metabolism C) Developmental Signaling Pathways, D) Developmental Processes, and E) Meiosis. Dynamic change in GO terms related to each dominant theme are plotted here as the ratio of average Log2 intensity of expression of all significantly changed genes at each timepoint in a GO term over Average Log2 intensity across all timepoints for that GO term. Corresponding stages of spermatogenesis, including spermatogonia (SPG), spermatocyte (SPC), spermatid (SPT), and spermatozoa (SPZ) are indicated along the X axis.

Our analysis also reveals dynamic changes of signal transduction pathways throughout spermatogenesis (Figure 3C). Average gene expression of many developmental signaling pathways, including BMP, Notch, and MAPK signaling, are elevated towards the end of gestation and during the earliest stages of spermatogenesis, peaking between GD 16.5 and PND 3. Average expression in these developmental signaling pathways decreases dramatically between PND 14 and PND 18, as testicular formation and development give way to functional adult tissue.

GO terms for developmental processes (Figure 3D) and mitosis (Figure 3E) display a similar pattern of dramatic upregulation during peak testicular development, dropping off as testes mature and spermatogenesis progresses. For example, pathways involved in cell growth and differentiation, mitosis, and cellular morphogenesis and development, are generally elevated during gestation and the first week of life. Then, around PND 8, expression of genes in these pathways begins a gradual decrease. This decrease corresponds to the end stages of testis development and maturation and the beginning of spermatogenesis.

Discussion

Our systematic pathway-based approach distills complex genomic data into a quantitative description of pathway dynamics over the course of gonadal development and spermatogenesis. This analysis successfully captures well characterized developmental processes, offering a quantitative framework for assessing normal temporal dynamics of reproductive development and measuring any perturbation of these dynamics that could lead to pathology. Finally, by defining in vivo pathway dynamics, this analysis facilitates evaluation of the ability of emerging in vitro systems to capture important developmental pathways.

Pathway analysis captures dynamics of key events known to drive testicular development and spermatogenesis

The trends highlighted by our analysis are consistent with well characterized developmental processes described in the literature. For example, the notable peak in expression of pathways related to steroidogenesis and hormonal regulation observed in our analysis at GD 16.5 corresponds to the well characterized peak in testosterone known to drive male reproductive development [16, 34]. Furthermore, in this dataset, specific genes that are widely recognized in the literature for their roles in steroidogenesis, including, star, 3β-HSD, and C/EBPβ [35, 36] follow temporal expression patterns that are consistent with the average expression patterns reflected in pathway analysis. The significant increase in steroidogenesis during this phase has previously been identified as a critical initiator of testis development and masculinization of the fetus [16, 34]. Expression of a host of genes in the mouse reproductive tract has been shown to be modulated by estrogen and testosterone [37].

The dramatic proliferation of somatic cells that occurs early in testis development plays a role in promoting the male fate by increasing the number of SRY-producing cells and marks a key difference between male and female development [38]. Accordingly, in this analysis, we see that pathways that promote proliferation and mitosis are expressed in developing testes and then downregulated as functionally mature testes begin spermatogenesis. Conversely, meiosis in the testis does not begin until around PND5, with the initiation of the first wave of spermatogenesis [39]. This is clearly illustrated at the pathway level in our analysis. In addition, several meiosis-specific genes described in the literature, such as the family of synaptonemal complex proteins [40] follow expression trends consistent with overall pathway trends.

The onset of meiosis in this analysis is followed by a dramatic increase in expression of a host of specific genes known to play an important role in spermatogenesis. For example, by PND 30 there is a sharp increase in gene expression of protamines 1 and 2 and the transition proteins that facilitate the switch between histones and sperm-specific protamines [40]. General expression dynamics of GO terms related to spermatogenesis are consistent with expression dynamics for these genes with well-characterized roles in spermatogenesis.

During spermatogenesis, chromatin restructuring facilitates sperm compaction and regulation of DNA methylation [41, 42]. Precise regulation of these epigenetic processes is essential for sperm development as well as for appropriate expression of the paternal genome in the developing embryo [42]. The ubiquitin system plays an important role in performing the histone modifications that underlie this chromatin restructuring [43]. The prominent increase in expression of genes associated with ubiquitin mediated processes and epigenetic processes that is observed concurrently with spermatogenesis in our analysis illustrates the temporal dynamics of these well-described regulatory processes.

Our analysis also successfully captures the important role of signal transduction pathways in regulating development. At least 17 highly conserved signaling pathways are now recognized for their central role in guiding developmental processes [12, 44]. Many of these signaling pathways are specifically implicated in guiding the processes of gonadal differentiation and testicular development [45] and germ cell differentiation [46]. In the current analysis, we capture the increased expression of genes involved in these signal transduction pathways throughout gestation and testicular maturation. These signaling pathways are then downregulated as testis tissue achieves maturation and begins the process of meiosis and spermatogenesis.

Pathway analysis can facilitate discovery of new roles for pathways dynamically changed in testicular development

In addition to accurately illustrating these well characterized developmental processes, quantitative pathway analysis is also a powerful tool for providing new insight into the stagespecific regulation of signaling pathways involved in the unique and complex processes of gonadal differentiation and spermatogenesis. The precise balance of these signaling pathways is hypothesized to play a key role in male development by initiating the differentiation of the fetal Leydig cells that produce masculinizing hormones [47]. The current analysis shows a wide range of signal transduction pathways that go through dramatic changes in expression in testicular tissue over the course of the first wave of spermatogenesis. Further investigation of the fluctuations in these signaling pathways over time could provide insight into their roles in the regulation and maintenance of spermatogenesis.

We also find that pathways related to cellular metabolism of lipids and proteins follow the same pattern of expression as steroidogenesis pathways during spermatogenesis. If these pathways are in fact linked, this is consistent with the hypothesis that cellular metabolism pathways are a target of androgen action, allowing androgens to modulate the testis environment to promote spermatogenesis [16]. These observations illustrate that our pathway-based approach can provide quantitative information on the dynamic changes seen in a range of signaling pathways over the course of development. Deeper exploration of this pathway analysis may reveal additional novel pathways that are important in reproductive development.

Benefits and drawbacks of the quantitative pathway-based approach

There are many benefits to applying a pathway based approach to analyze temporal gene expression data. For example, we reduce the potential for overlooking key pathways whose subtle changes have large effects by considering the pathway as a whole as opposed to individual genes. We also reduce the amount of statistical noise, as entire gene networks are far less likely than individual genes to be significantly increased simply by chance. It is important to note that while average pathway expression provides an informative summary of pathway dynamics driving developmental processes, this method is not ideal for identification and characterization of single genes that serve as key developmental regulators. In addition, the quality of a pathway-based analysis is limited by the quality of the curation of each pathway. Indeed, there are several pathways enriched in our analysis (e.g. heart development and neural tube development) that are likely to be an artifact of genes that have simultaneous roles in multiple pathways or signal transduction that is highly conserved across a diverse range of developmental processes.

Applications for developmental toxicology: defining sensitive phases of development and generating complex, context dependent Adverse Outcome Pathways

In addition to providing insight into normal gonadal development and spermatogenesis, this quantitative gene ontology analysis offers a new lens through which to evaluate developmental pathology. This will be a particularly valuable tool for our field of developmental toxicology. Understanding the dynamics of signaling pathways can further define key phases of susceptibility to environmental factors. For example quantitative characterization of the pathway dynamics that drive steroid regulation can shed light on key windows of susceptibility of this process to endocrine disrupting chemicals [7, 48].

The challenge of regulatory chemical testing requirements and the vast number of chemicals yet to be tested will require innovative computational toxicology methods [49, 50]. Toxicity-related alterations in gene transcription and biological pathway dynamics have been proposed as valuable metrics for chemical risk assessment that could be generated by highthroughput methods [51, 52]. To that end, a quantitative pathway-based approach can be applied to predict and measure the effects of chemical exposure on signaling pathway dynamics. This approach is a powerful way to quantify changes in the developmental dynamics of signaling pathways in response to genetic mutations and environmental factors. Changes in the peaks, slopes and duration of the dynamic expression patterns of signaling pathways in response to toxicant exposure will provide a sensitive measure of reproductive developmental toxicity and offer insight into mechanisms of toxicity. Quantitative pathway-based characterization of signaling pathway dynamics could also inform mathematical models for in silico simulation of the specific impacts of gene changes or environmental exposures on developmental outcomes. Furthermore, quantifying the perturbation of developmental pathway dynamics in response to toxicant exposures could facilitate articulation of “Adverse Outcome Pathways”, which are emerging as an increasingly valuable tool for translating toxicological data for risk assessment [53]. Therefore, in addition to shedding light on normal developmental dynamics, this quantitative pathway- based approach provides a framework for quantifying deviation from normal developmental processes.

Supplementary Material

1
2

Table 2.3.

Full list of GO Terms Enriched Among Genes With Significantly Increased Expression Through Time

GOID GO Name # Genes
in GO
%Genes
Changed
%Genes
Present
Z-
Score
Parametric
p-value
48232 male gamete generation 194 53.3 70.6 11.94 4.0E-05
7283 Spermatogenesis 194 53.3 70.6 11.94 4.0E-05
19953 sexual reproduction 327 45 67.9 11.87 4.6E-05
3 Reproduction 492 35.5 65.2 9.62 5.2E-05
7276 gamete generation 278 41.8 66.2 9.60 5.1E-05
9566 Fertilization 48 62.9 72.9 7.55 2.0E-05
7338 single fertilization 48 61.8 70.8 7.27 2.1E-05
30317 sperm motility 15 75 106.7 6.43 3.7E-05
48515 spermatid differentiation 36 56.2 88.9 6.20 7.7E-05
7286 spermatid development 34 56.7 88.2 6.07 3.3E-05
7127 meiosis I 32 63.2 59.4 5.60 1.9E-04
6457 protein folding 238 29.5 72.7 4.84 1.2E-04
6512 ubiquitin cycle 433 25.3 83.1 4.84 7.7E-05
35036 sperm-egg recognition 12 66.7 100 4.78 1.5E-07
1539 ciliary or flagellar motility 6 100 66.7 4.57 1.7E-06
7129 Synapsis 9 75 88.9 4.54 2.2E-04
9988 cell-cell recognition 13 61.5 100 4.47 1.5E-07
51327 M phase of meiotic cell cycle 76 37.7 69.7 4.31 1.5E-04
7126 Meiosis 76 37.7 69.7 4.31 1.5E-04
7339 binding of sperm to zona pellucida 11 63.6 100 4.30 1.6E-07
51321 meiotic cell cycle 77 37 70.1 4.21 1.5E-04
48240 sperm capacitation 5 100 60 3.96 3.3E-05
6644 phospholipid metabolic process 127 30.1 81.1 3.90 9.7E-05
2483 antigen processing and presentation of endogenous peptide antigen 8 80 62.5 3.90 4.8E-05
19885 antigen processing and presentation of endogenous peptide antigen via MHC class I 8 80 62.5 3.90 4.8E-05
30163 protein catabolic process 220 27.2 71.8 3.85 9.4E-05
6643 membrane lipid metabolic process 173 28 76.3 3.77 9.0E-05
6511 ubiquitin-dependent protein catabolic process 165 28.9 69.1 3.77 6.9E-05
19941 modification-dependent protein catabolic process 167 28.4 69.5 3.65 6.9E-05
43632 modification-dependent macromolecule catabolic process 167 28.4 69.5 3.65 6.9E-05
8654 phospholipid biosynthetic process 67 33.9 83.6 3.65 3.7E-05
6352 transcription initiation 45 37.8 82.2 3.62 5.1E-05
44265 cellular macromolecule catabolic process 319 25.1 64.9 3.58 5.9E-05
6516 glycoprotein catabolic process 16 62.5 50 3.58 1.4E-04
6913 nucleocytoplasmic transport 127 29.7 71.7 3.55 1.2E-04
51603 proteolysis involved in cellular protein catabolic process 170 28 69.4 3.54 6.9E-05
6464 protein modification process 1609 19.5 78.3 3.54 8.7E-05
6508 proteolysis 806 21.3 70.5 3.49 8.2E-05
6611 protein export from nucleus 16 50 87.5 3.46 1.3E-04
9057 macromolecule catabolic process 387 23.8 67.2 3.46 7.8E-05
22414 reproductive process 248 26.1 63.3 3.46 5.4E-05
44257 cellular protein catabolic process 172 27.5 69.8 3.43 6.9E-05
46467 membrane lipid biosynthetic process 85 31.3 78.8 3.42 3.4E-05
65004 protein-DNA complex assembly 172 29.2 51.7 3.39 5.0E-05
7342 fusion of sperm to egg plasma membrane 9 66.7 66.7 3.38 8.0E-07
51169 nuclear transport 115 29.6 70.4 3.34 1.3E-04
43412 biopolymer modification 1677 19.2 78.1 3.31 8.6E-05
7017 microtubule-based process 216 25.6 72.2 3.28 9.2E-05
44267 cellular protein metabolic process 3258 18.2 74 3.26 9.3E-05
45862 positive regulation of proteolysis 5 75 80 3.21 3.1E-05
7131 meiotic recombination 17 75 23.5 3.21 6.4E-06
6003 fructose 2\,6-bisphosphate metabolic process 4 75 100 3.21 2.5E-04
9894 regulation of catabolic process 19 50 63.2 3.21 2.1E-05
44260 cellular macromolecule metabolic process 3301 18.1 74.1 3.14 9.3E-05
19538 protein metabolic process 3404 18.1 74 3.12 9.2E-05
6986 response to unfolded protein 62 38.5 41.9 3.12 3.9E-05
51789 response to protein stimulus 62 38.5 41.9 3.12 3.9E-05
19318 hexose metabolic process 174 26.5 67.2 3.09 7.0E-05
22403 cell cycle phase 289 23.5 78.2 3.06 1.2E-04
9056 catabolic process 639 21 72.1 2.97 7.2E-05
279 M phase 232 23.9 81 2.97 1.3E-04
7340 acrosome reaction 12 57.1 58.3 2.96 4.5E-07
45026 plasma membrane fusion 10 57.1 70 2.96 8.0E-07
19883 antigen processing and presentation of endogenous antigen 11 57.1 63.6 2.96 4.8E-05
5996 monosaccharide metabolic process 178 25.8 67.4 2.93 7.0E-05
42176 regulation of protein catabolic process 14 50 71.4 2.93 2.5E-05
6515 misfolded or incompletely synthesized protein catabolic process 19 50 52.6 2.93 1.9E-04
30433 ER-associated protein catabolic process 18 50 55.6 2.93 1.9E-04
6493 protein amino acid O-linked glycosylation 16 50 62.5 2.93 1.7E-04
6367 transcription initiation from RNA polymerase II promoter 25 40 80 2.92 7.1E-05
43687 post-translational protein modification 1375 19.1 79.1 2.90 8.5E-05
51170 nuclear import 80 29.5 76.2 2.87 1.2E-04
43285 biopolymer catabolic process 285 23.2 71.2 2.78 9.5E-05
30503 regulation of cell redox homeostasis 7 60 71.4 2.68 1.8E-05
7128 meiotic prophase I 4 60 125 2.68 1.0E-07
7130 synaptonemal complex assembly 6 60 83.3 2.68 1.1E-04
51324 prophase 4 60 125 2.68 1.0E-07
6000 fructose metabolic process 13 60 38.5 2.68 2.5E-04
6072 glycerol-3-phosphate metabolic process 7 60 71.4 2.68 4.7E-05
42787 protein ubiquitination during ubiquitin-dependent protein catabolic process 5 60 100 2.68 1.2E-04
9191 ribonucleoside diphosphate catabolic process 5 60 100 2.68 1.2E-05
46470 phosphatidylcholine metabolic process 7 60 71.4 2.68 3.4E-04
31365 N-terminal protein amino acid modification 6 60 83.3 2.68 3.6E-04
6606 protein import into nucleus 79 28.8 74.7 2.68 1.2E-04
7001 chromosome organization and biogenesis (sensu Eukaryota) 390 22.1 64.9 2.66 1.1E-04
45582 positive regulation of T cell differentiation 11 45.5 100 2.66 1.4E-04
51168 nuclear export 40 34.6 65 2.58 2.1E-04
6096 glycolysis 76 30.2 56.6 2.54 1.8E-05
6006 glucose metabolic process 133 25.8 66.9 2.53 4.8E-05
51276 chromosome organization and biogenesis 399 21.5 66.4 2.45 1.1E-04
7018 microtubule-based movement 115 26.3 66.1 2.45 6.6E-05
18342 protein prenylation 17 41.7 70.6 2.42 1.2E-04
16311 dephosphorylation 146 24 82.9 2.38 1.4E-04
48002 antigen processing and presentation of peptide antigen 37 30.6 97.3 2.37 1.1E-04
46164 alcohol catabolic process 93 27.8 58.1 2.35 2.7E-05
8037 cell recognition 41 31.2 78 2.35 3.8E-07
6944 membrane fusion 31 37.5 51.6 2.34 8.7E-05
18346 protein amino acid prenylation 13 44.4 69.2 2.32 1.5E-04
46165 alcohol biosynthetic process 27 35 74.1 2.31 7.4E-05
46364 monosaccharide biosynthetic process 27 35 74.1 2.31 7.4E-05
19319 hexose biosynthetic process 27 35 74.1 2.31 7.4E-05
6066 alcohol metabolic process 300 21.6 72.7 2.23 7.1E-05
7049 cell cycle 762 19.4 74.4 2.22 1.1E-04
6007 glucose catabolic process 86 27.5 59.3 2.22 2.5E-05
51252 regulation of RNA metabolic process 17 38.5 76.5 2.20 3.5E-04
44248 cellular catabolic process 510 20.2 69.8 2.18 6.4E-05
32446 protein modification by small protein conjugation 75 26.2 81.3 2.17 6.3E-05
6338 chromatin remodeling 52 28.9 73.1 2.17 8.6E-05
46365 monosaccharide catabolic process 91 26.9 57.1 2.14 2.5E-05
19320 hexose catabolic process 91 26.9 57.1 2.14 2.5E-05
46916 transition metal ion homeostasis 49 30 61.2 2.08 6.1E-05
31497 chromatin assembly 142 25.4 44.4 2.03 3.6E-05
6333 chromatin assembly or disassembly 180 23.6 49.4 1.95 7.0E-05

Table 2.4.

Full list of GO Terms Enriched Among Genes With Significantly Decreased Expression Through Time

GOID GO Name # Genes
in GO
% Genes
Changed
%
Genes
Present
Z-
Score
Parametric
p-value
9653 anatomical structure morphogenesis 1089 37.5 80.2 7.35 8.8E-05
9987 cellular process 12349 28.7 67 6.42 1.3E-04
32502 developmental process 3292 31.8 75.6 6.27 1.2E-04
48856 anatomical structure development 2002 33.4 74.8 6.16 9.9E-05
9058 biosynthetic process 1471 34.6 70 5.87 1.4E-04
902 cell morphogenesis 485 39.4 77.9 5.61 7.9E-05
32989 cellular structure morphogenesis 485 39.4 77.9 5.61 7.9E-05
9887 organ morphogenesis 457 39.2 82.1 5.49 8.6E-05
7167 enzyme linked receptor protein signaling pathway 278 43.7 71.6 5.42 9.7E-05
30036 actin cytoskeleton organization and biogenesis 196 46.6 74.5 5.42 7.1E-05
1525 angiogenesis 132 48.3 89.4 5.29 6.2E-05
9790 embryonic development 362 39.2 94.5 5.23 6.1E-05
30029 actin filament-based process 207 45.2 74.9 5.18 7.0E-05
7507 heart development 133 45.8 108.3 5.18 5.3E-05
51301 cell division 218 42.9 90.8 5.15 1.7E-04
35295 tube development 128 46.9 100 5.15 5.3E-05
7275 multicellular organismal development 2140 31.9 77.5 5.05 1.1E-04
48646 anatomical structure formation 173 44.4 92.5 5.04 7.4E-05
1944 vasculature development 190 42.9 93.2 4.87 7.2E-05
16043 cellular component organization and biogenesis 2656 31.4 70.2 4.86 1.2E-04
8152 metabolic process 8113 28.8 76.1 4.83 1.3E-04
44238 primary metabolic process 7338 29 75.1 4.83 1.3E-04
48731 system development 1704 32.5 74.9 4.82 1.0E-04
48514 blood vessel morphogenesis 162 44 92.6 4.78 7.5E-05
1568 blood vessel development 187 42.5 93 4.71 7.3E-05
35239 tube morphogenesis 83 48.9 106 4.68 6.2E-05
55008 cardiac muscle morphogensis 4 100 200 4.67 5.5E-05
44237 cellular metabolic process 7311 28.9 75.4 4.65 1.3E-04
1763 morphogenesis of a branching structure 49 54.7 108.2 4.59 6.3E-05
9059 macromolecule biosynthetic process 899 34.8 65.5 4.48 1.5E-04
48754 branching morphogenesis of a tube 46 55.1 106.5 4.48 5.1E-05
55010 ventricular cardiac muscle morphogenesis 4 100 175 4.37 5.0E-05
7399 nervous system development 658 35.2 74.3 4.25 1.0E-04
65007 biological regulation 4497 29.6 74.5 4.21 1.2E-04
22610 biological adhesion 645 35.4 70.5 4.20 8.5E-05
7155 cell adhesion 645 35.4 70.5 4.20 8.5E-05
278 mitotic cell cycle 249 39.6 81.1 4.13 1.3E-04
7178 transmembrane receptor protein serine/threonine kinase signaling pathway 87 50 71.3 4.13 1.2E-04
15669 gas transport 17 81.8 64.7 4.12 8.7E-05
50789 regulation of biological process 4133 29.7 75.1 4.11 1.3E-04
6996 organelle organization and biogenesis 1201 33.1 65.9 4.10 1.1E-04
30865 cortical cytoskeleton organization and biogenesis 14 76.9 92.9 4.08 1.5E-04
48513 organ development 1345 32.2 76.4 4.08 1.0E-04
7067 mitosis 168 41.7 85.7 4.04 1.4E-04
87 M phase of mitotic cell cycle 170 41.5 86.5 4.04 1.4E-04
50793 regulation of developmental process 256 38.8 85.5 4.04 7.9E-05
7169 transmembrane receptor protein tyrosine kinase signaling pathway 177 42.1 75.1 4.00 8.3E-05
9880 embryonic pattern specification 41 55.3 92.7 3.96 7.9E-05
8283 cell proliferation 648 35.3 63 3.93 9.8E-05
22402 cell cycle process 646 34.9 69.2 3.92 1.4E-04
43170 macromolecule metabolic process 6411 28.8 74.7 3.91 1.3E-04
22603 regulation of anatomical structure morphogenesis 46 53.7 89.1 3.89 3.8E-05
8360 regulation of cell shape 46 53.7 89.1 3.88 3.8E-05
22604 regulation of cell morphogenesis 46 53.7 89.1 3.88 3.8E-05
6412 translation 656 35.2 61.4 3.87 1.4E-04
48644 muscle morphogenesis 6 80 166.7 3.80 5.5E-05
7049 cell cycle 762 33.7 74.4 3.77 1.3E-04
8150 biological_process 14509 27.6 67.7 3.77 1.3E-04
30323 respiratory tube development 54 51.1 87 3.76 3.3E-05
22403 cell cycle phase 289 37.6 78.2 3.69 1.2E-04
7010 cytoskeleton organization and biogenesis 504 35.5 68.3 3.67 9.3E-05
30900 forebrain development 65 46.3 103.1 3.60 8.3E-05
31032 actomyosin structure organization and biogenesis 25 63.2 76 3.58 8.3E-05
30324 lung development 53 50 86.8 3.55 3.5E-05
9792 embryonic development ending in birth or egg hatching 149 39.2 102.7 3.48 4.8E-05
15671 oxygen transport 16 77.8 56.2 3.45 1.1E-04
43009 chordate embryonic development 147 39.1 102.7 3.42 4.9E-05
279 M phase 232 37.8 81 3.41 1.3E-04
51128 regulation of cellular component organization and biogenesis 68 46.6 85.3 3.40 9.8E-05
50794 regulation of cellular process 3752 29.3 74.9 3.39 1.2E-04
45765 regulation of angiogenesis 34 55.6 79.4 3.37 1.5E-04
8593 regulation of Notch signaling pathway 5 100 80 3.30 2.0E-05
48013 ephrin receptor signaling pathway 3 100 133.3 3.30 4.2E-05
48468 cell development 1610 30.8 74.2 3.27 1.3E-04
19538 protein metabolic process 3404 29.4 74 3.26 1.3E-04
6817 phosphate transport 84 44.6 77.4 3.25 1.2E-04
6694 steroid biosynthetic process 75 46.3 72 3.24 5.7E-05
6270 DNA replication initiation 26 64.3 53.8 3.17 1.4E-04
44249 cellular biosynthetic process 646 33.1 74.9 3.16 1.4E-04
30509 BMP signaling pathway 26 57.1 80.8 3.14 1.5E-04
6729 tetrahydrobiopterin biosynthetic process 6 83.3 100 3.13 1.8E-04
45995 regulation of embryonic development 7 83.3 85.7 3.13 2.1E-06
46146 tetrahydrobiopterin metabolic process 6 83.3 100 3.13 1.8E-04
51291 protein heterooligomerization 10 83.3 60 3.13 2.8E-05
8064 regulation of actin polymerization and/or depolymerization 41 51.6 75.6 3.12 9.1E-05
30832 regulation of actin filament length 42 51.6 73.8 3.12 9.1E-05
48546 digestive tract morphogenesis 10 66.7 120 3.12 7.8E-06
51169 nuclear transport 115 42 70.4 3.09 9.8E-05
9220 pyrimidine ribonucleotide biosynthetic process 16 70 62.5 3.08 6.8E-05
6275 regulation of DNA replication 19 70 52.6 3.08 1.5E-04
30866 cortical actin cytoskeleton organization and biogenesis 11 70 90.9 3.08 1.9E-04
8088 axon cargo transport 14 70 71.4 3.08 8.9E-05
7439 ectodermal gut development 8 75 100 3.08 1.0E-05
48567 ectodermal gut morphogenesis 8 75 100 3.08 1.0E-05
44255 cellular lipid metabolic process 542 33.2 81.2 3.06 1.4E-04
32990 cell part morphogenesis 249 36.3 80.7 3.06 1.0E-04
48858 cell projection morphogenesis 249 36.3 80.7 3.06 1.0E-04
30030 cell projection organization and biogenesis 249 36.3 80.7 3.06 1.0E-04
6403 RNA localization 49 50 69.4 3.05 1.7E-04
6790 sulfur metabolic process 78 45.3 67.9 3.04 1.0E-04
7266 Rho protein signal transduction 102 41.5 80.4 3.00 1.6E-04
16125 sterol metabolic process 73 44.1 80.8 3.00 7.3E-05
1501 skeletal development 205 37.6 72.7 2.98 1.2E-04
6221 pyrimidine nucleotide biosynthetic process 22 58.8 77.3 2.98 9.7E-05
30154 cell differentiation 2098 29.9 78.6 2.97 1.2E-04
48869 cellular developmental process 2098 29.9 78.6 2.97 1.2E-04
904 cellular morphogenesis during differentiation 182 37.8 78.6 2.97 1.1E-04
48332 mesoderm morphogenesis 24 51.9 112.5 2.94 8.7E-05
43405 regulation of MAPK activity 77 44.4 70.1 2.93 9.7E-05
46164 alcohol catabolic process 93 44.4 58.1 2.93 1.3E-04
59 protein import into nucleus\, docking 15 60 100 2.90 1.6E-04
51261 protein depolymerization 34 50 88.2 2.87 9.3E-05
7015 actin filament organization 50 47.4 76 2.86 3.9E-05
7179 transforming growth factor beta receptor signaling pathway 57 47.4 66.7 2.86 1.1E-04
15931 nucleobase\, nucleoside\, nucleotide and nucleic acid transport 54 47.4 70.4 2.86 2.4E-04
35112 genitalia morphogenesis 1 100 300 2.86 2.3E-07
7213 acetylcholine receptor signaling\, muscarinic pathway 6 100 50 2.86 1.8E-05
48010 vascular endothelial growth factor receptor signaling pathway 2 100 150 2.86 2.0E-05
30513 positive regulation of BMP signaling pathway 3 100 100 2.86 2.5E-04
31529 ruffle organization and biogenesis 3 100 100 2.86 3.4E-04
6290 pyrimidine dimer repair 4 100 75 2.86 3.1E-05
6435 threonyl-tRNA aminoacylation 3 100 100 2.86 9.7E-05
7043 intercellular junction assembly 9 100 33.3 2.86 1.4E-06
6598 polyamine catabolic process 3 100 100 2.86 1.7E-04
30538 embryonic genitalia morphogenesis 1 100 300 2.86 2.3E-07
6695 cholesterol biosynthetic process 25 55 80 2.85 4.1E-05
46365 monosaccharide catabolic process 91 44.2 57.1 2.84 1.3E-04
19320 hexose catabolic process 91 44.2 57.1 2.84 1.3E-04
8154 actin polymerization and/or depolymerization 54 46.3 75.9 2.83 8.3E-05
50658 RNA transport 47 48.5 70.2 2.81 1.8E-04
51236 establishment of RNA localization 47 48.5 70.2 2.81 1.8E-04
50657 nucleic acid transport 47 48.5 70.2 2.81 1.8E-04
32787 monocarboxylic acid metabolic process 225 35.8 84.4 2.81 1.3E-04
46907 intracellular transport 737 32 73.7 2.81 1.4E-04
6629 lipid metabolic process 650 32.2 78.3 2.80 1.5E-04
51170 nuclear import 80 42.6 76.2 2.79 8.2E-05
35023 regulation of Rho protein signal transduction 72 42.2 88.9 2.78 1.8E-04
42127 regulation of cell proliferation 425 34 67.1 2.78 9.4E-05
51028 mRNA transport 43 50 65.1 2.77 2.0E-04
48568 embryonic organ development 29 50 96.6 2.77 2.8E-05
44260 cellular macromolecule metabolic process 3301 29.1 74.1 2.77 1.3E-04
44267 cellular protein metabolic process 3258 29.1 74 2.77 1.3E-04
45454 cell redox homeostasis 58 44.7 81 2.77 8.9E-05
32501 multicellular organismal process 4035 29.2 52.9 2.76 1.1E-04
9218 pyrimidine ribonucleotide metabolic process 17 63.6 64.7 2.76 6.8E-05
1676 long-chain fatty acid metabolic process 16 63.6 68.8 2.76 3.0E-04
48628 myoblast maturation 29 55.6 62.1 2.75 5.1E-05
6913 nucleocytoplasmic transport 127 39.6 71.7 2.75 9.3E-05
7163 establishment and/or maintenance of cell polarity 33 52.2 69.7 2.75 1.5E-05
7369 gastrulation 51 43.4 103.9 2.73 6.4E-05
8203 cholesterol metabolic process 67 43.4 79.1 2.73 6.0E-05
51129 negative regulation of cell organization and biogenesis 34 48.4 91.2 2.71 9.3E-05
6606 protein import into nucleus 79 42.4 74.7 2.70 8.5E-05
48557 embryonic digestive tract morphogenesis 6 66.7 150 2.70 1.4E-06
48547 gut morphogenesis 9 66.7 100 2.70 1.0E-05
30510 regulation of BMP signaling pathway 13 66.7 69.2 2.70 1.6E-04
21915 neural tube development 37 45.2 113.5 2.70 6.9E-05
43549 regulation of kinase activity 193 37 69.9 2.69 1.2E-04
48699 generation of neurons 307 34.3 81.8 2.69 9.8E-05
16050 vesicle organization and biogenesis 9 80 55.6 2.68 2.2E-04
40016 embryonic cleavage 5 80 100 2.68 9.3E-05
8215 spermine metabolic process 6 80 83.3 2.68 6.2E-06
15012 heparan sulfate proteoglycan biosynthetic process 8 80 62.5 2.68 2.5E-04
46128 purine ribonucleoside metabolic process 6 80 83.3 2.68 7.4E-05
48488 synaptic vesicle endocytosis 11 80 45.5 2.68 1.5E-04
6400 tRNA modification 7 80 71.4 2.68 1.8E-04
30325 adrenal gland development 6 80 83.3 2.68 2.2E-04
7440 foregut morphogenesis 4 80 125 2.68 1.5E-05
1704 formation of primary germ layer 25 50 104 2.67 9.4E-05
16126 sterol biosynthetic process 31 50 83.9 2.67 7.4E-05
43406 positive regulation of MAPK activity 52 47.1 65.4 2.67 9.9E-05
47496 vesicle transport along microtubule 5 71.4 140 2.66 5.4E-05
9396 folic acid and derivative biosynthetic process 6 71.4 116.7 2.66 1.3E-04
30838 positive regulation of actin filament polymerization 7 71.4 100 2.66 2.0E-04
43525 positive regulation of neuron apoptosis 5 71.4 140 2.66 2.9E-04
7265 Ras protein signal transduction 172 37.4 71.5 2.66 1.7E-04
7409 axonogenesis 158 37.4 77.8 2.66 1.2E-04
50673 epithelial cell proliferation 23 52.4 91.3 2.65 8.4E-05
51338 regulation of transferase activity 198 36.7 70.2 2.64 1.2E-04
6007 glucose catabolic process 86 43.1 59.3 2.63 1.2E-04
22008 neurogenesis 330 33.8 82.4 2.63 1.1E-04
6461 protein complex assembly 203 36.8 65.5 2.62 1.3E-04
45859 regulation of protein kinase activity 186 36.9 69.9 2.61 1.3E-04
6631 fatty acid metabolic process 166 36.4 86.1 2.59 1.6E-04
1707 mesoderm formation 23 50 104.3 2.57 1.0E-04
96 sulfur amino acid metabolic process 21 57.1 66.7 2.56 1.1E-04
55001 muscle cell development 20 57.1 70 2.56 6.3E-05
6261 DNA-dependent DNA replication 73 43.5 63 2.55 1.2E-04
48667 neuron morphogenesis during differentiation 166 36.6 78.9 2.55 1.2E-04
48812 neurite morphogenesis 166 36.6 78.9 2.55 1.2E-04
1569 patterning of blood vessels 18 52.6 105.6 2.54 5.6E-05
51098 regulation of binding 23 52.6 82.6 2.54 1.8E-04
48627 myoblast development 30 52.6 63.3 2.54 5.1E-05
51052 regulation of DNA metabolic process 37 52.6 51.4 2.54 1.3E-04
8610 lipid biosynthetic process 256 34.7 78.9 2.53 1.1E-04
51726 regulation of cell cycle 461 33.5 60.3 2.52 1.3E-04
74 regulation of progression through cell cycle 459 33.5 59.9 2.51 1.3E-04
6082 organic acid metabolic process 521 32.2 79.3 2.51 1.3E-04
19752 carboxylic acid metabolic process 520 32.2 79.4 2.51 1.3E-04
8285 negative regulation of cell proliferation 189 37.3 58.2 2.48 9.9E-05
7417 central nervous system development 224 35.1 77.7 2.47 8.2E-05
16525 negative regulation of angiogenesis 15 58.3 80 2.47 1.2E-04
48565 gut development 15 58.3 80 2.47 8.9E-06
30833 regulation of actin filament polymerization 17 58.3 70.6 2.46 1.5E-04
40007 growth 252 34.5 78.2 2.46 9.9E-05
48519 negative regulation of biological process 1018 30.6 76.1 2.44 1.2E-04
10003 gastrulation (sensu Mammalia) 18 52.9 94.4 2.43 2.7E-05
46849 bone remodeling 99 38.4 86.9 2.43 1.4E-04
51216 cartilage development 37 45.5 89.2 2.42 9.3E-05
16331 morphogenesis of embryonic epithelium 52 41.5 101.9 2.42 7.3E-05
22607 cellular component assembly 536 32.6 61.8 2.41 1.4E-04
1503 ossification 89 39 86.5 2.41 1.5E-04
15980 energy derivation by oxidation of organic compounds 81 40.7 72.8 2.41 1.2E-04
2009 morphogenesis of an epithelium 106 37 101.9 2.41 1.1E-04
44272 sulfur compound biosynthetic process 35 48 71.4 2.39 1.6E-04
48523 negative regulation of cellular process 967 30.7 74.6 2.39 1.2E-04
31175 neurite development 192 35.3 79.7 2.38 1.1E-04
35088 establishment and/or maintenance of apical/basal cell polarity 12 60 83.3 2.37 2.5E-05
50818 regulation of coagulation 11 60 90.9 2.37 5.1E-05
8202 steroid metabolic process 145 36.5 79.3 2.36 9.8E-05
31214 biomineral formation 90 38.5 86.7 2.33 1.5E-04
31110 regulation of microtubule polymerization or depolymerization 14 53.3 107.1 2.32 1.2E-04
50678 regulation of epithelial cell proliferation 18 53.3 83.3 2.32 9.4E-05
8637 apoptotic mitochondrial 18 53.3 83.3 2.32 8.0E-05
17038 protein import 93 39.1 74.2 2.31 1.0E-04
51270 regulation of cell motility 67 40.4 85.1 2.31 6.3E-05
44275 cellular carbohydrate catabolic process 110 39.7 57.3 2.31 1.3E-04
48469 cell maturation 83 40 72.3 2.31 4.6E-05
14031 mesenchymal cell development 28 45.2 110.7 2.31 4.7E-05
6241 CTP biosynthetic process 13 62.5 61.5 2.28 6.6E-06
9209 pyrimidine ribonucleoside triphosphate biosynthetic process 13 62.5 61.5 2.28 6.6E-06
6098 pentose-phosphate shunt 9 62.5 88.9 2.28 2.4E-04
97 sulfur amino acid biosynthetic process 12 62.5 66.7 2.28 9.6E-05
1836 release of cytochrome c from mitochondria 10 62.5 80 2.28 1.3E-04
6465 signal peptide processing 8 62.5 100 2.28 3.1E-06
6740 NADPH regeneration 9 62.5 88.9 2.28 2.4E-04
10165 response to X-ray 5 62.5 160 2.28 2.1E-04
43648 dicarboxylic acid metabolic process 12 62.5 66.7 2.28 1.4E-04
50920 regulation of chemotaxis 10 62.5 80 2.28 1.8E-04
50921 positive regulation of chemotaxis 9 62.5 88.9 2.28 1.8E-04
1837 epithelial to mesenchymal transition 6 62.5 133.3 2.28 3.7E-05
9208 pyrimidine ribonucleoside triphosphate metabolic process 13 62.5 61.5 2.28 6.6E-06
46036 CTP metabolic process 13 62.5 61.5 2.28 6.6E-06
51347 positive regulation of transferase activity 118 37.5 74.6 2.27 1.2E-04
1839 neural plate morphogenesis 35 43.2 105.7 2.26 9.1E-05
7420 brain development 152 35.3 89.5 2.24 8.8E-05
6066 alcohol metabolic process 300 33.5 72.7 2.24 1.0E-04
16049 cell growth 139 36.6 72.7 2.23 6.3E-05
6096 glycolysis 76 41.9 56.6 2.23 9.1E-05
7498 mesoderm development 51 41.9 84.3 2.23 6.8E-05
75 cell cycle checkpoint 47 46.2 55.3 2.23 1.2E-04
45333 cellular respiration 36 46.2 72.2 2.23 1.4E-04
51168 nuclear export 40 46.2 65 2.23 1.0E-04
1843 neural tube closure 22 46.2 118.2 2.23 1.0E-04
16337 cell-cell adhesion 250 34.6 63.6 2.23 6.4E-05
30182 neuron differentiation 273 33.5 78.8 2.22 1.1E-04
48562 embryonic organ morphogenesis 15 50 120 2.22 1.6E-06
30334 regulation of cell migration 58 40.8 84.5 2.22 7.2E-05
65009 regulation of a molecular function 365 32.8 71.8 2.22 1.5E-04
40012 regulation of locomotion 70 39.3 87.1 2.21 6.9E-05
42541 hemoglobin biosynthetic process 4 66.7 150 2.20 2.5E-04
20027 hemoglobin metabolic process 4 66.7 150 2.20 2.5E-04
6108 malate metabolic process 6 66.7 100 2.20 1.7E-04
48558 embryonic gut morphogenesis 5 66.7 120 2.20 2.1E-06
8156 negative regulation of DNA replication 12 66.7 50 2.20 2.5E-04
7028 cytoplasm organization and biogenesis 23 53.8 56.5 2.20 1.4E-04
15698 inorganic anion transport 153 36 72.5 2.20 1.6E-04
30239 myofibril assembly 19 53.8 68.4 2.20 5.1E-05
31111 negative regulation of microtubule polymerization or depolymerization 12 53.8 108.3 2.20 1.4E-04
55002 striated muscle cell development 19 53.8 68.4 2.20 5.1E-05
9165 nucleotide biosynthetic process 149 36.1 72.5 2.19 1.3E-04
2027 cardiac chronotropy 2 75 200 2.18 4.1E-05
9966 regulation of signal transduction 411 32.1 78.8 2.17 1.6E-04
40008 regulation of growth 169 35.1 79.3 2.17 1.0E-04
48762 mesenchymal cell differentiation 29 43.8 110.3 2.16 4.7E-05
187 activation of MAPK activity 48 43.8 66.7 2.16 9.9E-05
51246 regulation of protein metabolic process 276 33.3 77.2 2.16 1.2E-04
6284 base-excision repair 24 47.6 87.5 2.15 1.0E-04
7281 germ cell development 34 47.6 61.8 2.15 1.9E-05
8645 hexose transport 30 47.6 70 2.15 2.6E-04
15749 monosaccharide transport 30 47.6 70 2.15 2.6E-04
9952 anterior/posterior pattern formation 83 37.7 92.8 2.15 1.1E-04
30041 actin filament polymerization 28 47.6 75 2.15 1.2E-04
30282 bone mineralization 26 47.6 80.8 2.15 1.8E-04
16477 cell migration 285 33 80.7 2.15 9.0E-05
21700 developmental maturation 99 37.8 74.7 2.15 6.9E-05
43623 cellular protein complex assembly 48 42.9 72.9 2.14 1.1E-04
6259 DNA metabolic process 733 31 68.8 2.13 1.2E-04
6357 regulation of transcription from RNA polymerase II promoter 431 32.1 70.8 2.12 1.1E-04
31589 cell-substrate adhesion 74 38.7 83.8 2.12 6.1E-05
7219 Notch signaling pathway 51 40.9 86.3 2.11 5.6E-05
40029 regulation of gene expression\, epigenetic 64 40.9 68.8 2.11 1.9E-04
48666 neuron development 213 33.9 80.3 2.11 1.2E-04
8361 regulation of cell size 142 35.8 74.6 2.11 6.2E-05
9798 axis specification 17 50 94.1 2.09 1.4E-04
31570 DNA integrity checkpoint 26 50 61.5 2.09 4.0E-06
31109 microtubule polymerization or depolymerization 15 50 106.7 2.09 1.2E-04
45860 positive regulation of protein kinase activity 110 37 73.6 2.08 1.3E-04
7026 negative regulation of microtubule depolymerization 10 54.5 110 2.08 1.6E-04
7019 microtubule depolymerization 11 54.5 100 2.08 1.6E-04
31114 regulation of microtubule depolymerization 10 54.5 110 2.08 1.6E-04
9117 nucleotide metabolic process 229 34 70.7 2.06 1.3E-04
48771 tissue remodeling 105 36.2 89.5 2.05 1.6E-04
16052 carbohydrate catabolic process 115 37.9 57.4 2.03 1.3E-04
6220 pyrimidine nucleotide metabolic process 41 45.5 53.7 1.97 9.7E-05
271 polysaccharide biosynthetic process 24 45.5 91.7 1.97 1.4E-04
6793 phosphorus metabolic process 912 29.9 76.6 1.89 1.2E-04
6796 phosphate metabolic process 912 29.9 76.6 1.89 0.0001225

Highlights.

  • Quantitative pathway analysis of gene expression through time in testis development concisely summarizes pathway dynamics across development

  • The result of this analysis successfully captures and quantifies key processes of male reproductive development described in the literature

  • This approach provides a framework for quantifying perturbation of normal developmental dynamics by environmental factors

Footnotes

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

References

  • 1.Carlsen E, Giwercman A, Keiding N, Skakkebaek NE. Evidence for decreasing quality of semen during past 50 years. BMJ. 1992;305(6854):609–613. doi: 10.1136/bmj.305.6854.609. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Swan SH, Elkin EP, Fenster L. Have sperm densities declined? A reanalysis of global trend data. Environmental health perspectives. 1997;105(11):1228–1232. doi: 10.1289/ehp.971051228. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Rolland M, Le Moal J, Wagner V, Royere D, De Mouzon J. Decline in semen concentration and morphology in a sample of 26,609 men close to general population between 1989 and 2005 in France. Hum Reprod. 2013;28(2):462–470. doi: 10.1093/humrep/des415. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Andersen AG, Jensen TK, Carlsen E, Jorgensen N, Andersson AM, Krarup T, et al. High frequency of sub-optimal semen quality in an unselected population of young men. Hum Reprod. 2000;15(2):366–372. doi: 10.1093/humrep/15.2.366. [DOI] [PubMed] [Google Scholar]
  • 5.Jensen TK, Carlsen E, Jorgensen N, Berthelsen JG, Keiding N, Christensen K, et al. Poor semen quality may contribute to recent decline in fertility rates. Hum Reprod. 2002;17(6):1437–1440. doi: 10.1093/humrep/17.6.1437. [DOI] [PubMed] [Google Scholar]
  • 6.Skakkebaek NE, Rajpert-De Meyts E, Main KM. Testicular dysgenesis syndrome: an increasingly common developmental disorder with environmental aspects. Hum Reprod. 2001;16(5):972–978. doi: 10.1093/humrep/16.5.972. [DOI] [PubMed] [Google Scholar]
  • 7.Sharpe RM, Skakkebaek NE. Testicular dysgenesis syndrome: mechanistic insights and potential new downstream effects. Fertil Steril. 2008;89(2 Suppl):e33–e38. doi: 10.1016/j.fertnstert.2007.12.026. [DOI] [PubMed] [Google Scholar]
  • 8.Berruti G. Signaling events during male germ cell differentiation: bases and perspectives. Front Biosci. 1998;3:D1097–D1108. doi: 10.2741/a347. [DOI] [PubMed] [Google Scholar]
  • 9.Western P. Foetal germ cells: striking the balance between pluripotency and differentiation. Int J Dev Biol. 2009;53(2–3):393–409. doi: 10.1387/ijdb.082671pw. [DOI] [PubMed] [Google Scholar]
  • 10.Gray LE, Jr, Ostby J, Furr J, Price M, Veeramachaneni DN, Parks L. Perinatal exposure to the phthalates DEHP, BBP, and DINP, but not DEP, DMP, or DOTP, alters sexual differentiation of the male rat. Toxicol Sci. 2000;58(2):350–365. doi: 10.1093/toxsci/58.2.350. [DOI] [PubMed] [Google Scholar]
  • 11.Parks LG, Ostby JS, Lambright CR, Abbott BD, Klinefelter GR, Barlow NJ, et al. The plasticizer diethylhexyl phthalate induces malformations by decreasing fetal testosterone synthesis during sexual differentiation in the male rat. Toxicol Sci. 2000;58(2):339–349. doi: 10.1093/toxsci/58.2.339. [DOI] [PubMed] [Google Scholar]
  • 12.The National Academies Press; 2000. NRC, Scientific Frontiers in Developmental Toxicology and Risk Assessment. [PubMed] [Google Scholar]
  • 13.Marjani SL, Le Bourhis D, Vignon X, Heyman Y, Everts RE, Rodriguez-Zas SL, et al. Embryonic gene expression profiling using microarray analysis. Reproduction, fertility, and development. 2009;21(1):22–30. doi: 10.1071/rd08217. [DOI] [PubMed] [Google Scholar]
  • 14.Armit C. Developmental biology and databases: how to archive, find and query gene expression patterns using the world wide web. Organogenesis. 2007;3(2):70–73. doi: 10.4161/org.3.2.4942. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Escalier D. Impact of genetic engineering on the understanding of spermatogenesis. Human reproduction update. 2001;7(2):191–210. doi: 10.1093/humupd/7.2.191. [DOI] [PubMed] [Google Scholar]
  • 16.Verhoeven G, Willems A, Denolet E, Swinnen JV, De Gendt K. Androgens and spermatogenesis: lessons from transgenic mouse models. Philos Trans R Soc Lond B Biol Sci. 2010;365(1546):1537–1556. doi: 10.1098/rstb.2009.0117. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Small CL, Shima JE, Uzumcu M, Skinner MK, Griswold MD. Profiling gene expression during the differentiation and development of the murine embryonic gonad. Biol Reprod. 2005;72(2):492–501. doi: 10.1095/biolreprod.104.033696. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Shima JE, McLean DJ, McCarrey JR, Griswold MD. The murine testicular transcriptome: characterizing gene expression in the testis during the progression of spermatogenesis. Biol Reprod. 2004;71(1):319–330. doi: 10.1095/biolreprod.103.026880. [DOI] [PubMed] [Google Scholar]
  • 19.Clemente EJ, Furlong RA, Loveland KL, Affara NA. Gene expression study in the juvenile mouse testis: identification of stage-specific molecular pathways during spermatogenesis. Mamm Genome. 2006;17(9):956–975. doi: 10.1007/s00335-006-0029-3. [DOI] [PubMed] [Google Scholar]
  • 20.Bouma GJ, Hudson QJ, Washburn LL, Eicher EM. New candidate genes identified for controlling mouse gonadal sex determination and the early stages of granulosa and Sertoli cell differentiation. Biol Reprod. 2010;82(2):380–389. doi: 10.1095/biolreprod.109.079822. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Houmard B, Small C, Yang L, Naluai-Cecchini T, Cheng E, Hassold T, et al. Global gene expression in the human fetal testis and ovary. Biol Reprod. 2009;81(2):438–443. doi: 10.1095/biolreprod.108.075747. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Doniger SW, Salomonis N, Dahlquist KD, Vranizan K, Lawlor SC, Conklin BR. MAPPFinder: using Gene Ontology and GenMAPP to create a global gene-expression profile from microarray data. Genome Biol. 2003;4(1):R7. doi: 10.1186/gb-2003-4-1-r7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Dennis G, Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 2003;4(5):P3. [PubMed] [Google Scholar]
  • 24.Beissbarth T, Speed TP. GOstat: find statistically overrepresented Gene Ontologies within a group of genes. Bioinformatics. 2004;20(9):1464–1465. doi: 10.1093/bioinformatics/bth088. [DOI] [PubMed] [Google Scholar]
  • 25.Al-Shahrour F, Diaz-Uriarte R, Dopazo J. FatiGO: a web tool for finding significant associations of Gene Ontology terms with groups of genes. Bioinformatics. 2004;20(4):578–580. doi: 10.1093/bioinformatics/btg455. [DOI] [PubMed] [Google Scholar]
  • 26.Laiho A, Kotaja N, Gyenesei A, Sironen A. Transcriptome profiling of the murine testis during the first wave of spermatogenesis. PLoS One. 2013;8(4):e61558. doi: 10.1371/journal.pone.0061558. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Yu X, Griffith WC, Hanspers K, Dillman JF, 3rd, Ong H, Vredevoogd MA, et al. A system-based approach to interpret dose- and time-dependent microarray data: quantitative integration of gene ontology analysis for risk assessment. Toxicol Sci. 2006;92(2):560–577. doi: 10.1093/toxsci/kfj184. [DOI] [PubMed] [Google Scholar]
  • 28.Dillman JF, 3rd, Phillips CS, Dorsch LM, Croxton MD, Hege AI, Sylvester AJ, et al. Genomic analysis of rodent pulmonary tissue following bis-(2-chloroethyl) sulfide exposure. Chem Res Toxicol. 2005;18(1):28–34. doi: 10.1021/tx049745z. [DOI] [PubMed] [Google Scholar]
  • 29.Cunnigham ML. Putting the fun into functional toxicogenomics. Toxicol Sci. 2006;92(2):347–348. doi: 10.1093/toxsci/kfl027. [DOI] [PubMed] [Google Scholar]
  • 30.Yu X, Hong S, Moreira EG, Faustman EM. Improving in vitro Sertoli cell/gonocyte co-culture model for assessing male reproductive toxicity: Lessons learned from comparisons of cytotoxicity versus genomic responses to phthalates. Toxicol Appl Pharmacol. 2009;239(3):325–336. doi: 10.1016/j.taap.2009.06.014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Robinson JF, Guerrette Z, Yu X, Hong S, Faustman EM. A systems-based approach to investigate dose- and time-dependent methylmercury-induced gene expression response in C57BL/6 mouse embryos undergoing neurulation. Birth Defects Res B Dev Reprod Toxicol. 2010;89(3):188–200. doi: 10.1002/bdrb.20241. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Soukas A, Cohen P, Socci ND, Friedman JM. Leptin-specific patterns of gene expression in white adipose tissue. Genes Dev. 2000;14(8):963–980. [PMC free article] [PubMed] [Google Scholar]
  • 33.Dahlquist KD, Salomonis N, Vranizan K, Lawlor SC, Conklin BR. GenMAPP, a new tool for viewing and analyzing microarray data on biological pathways. Nat Genet. 2002;31(1):19–20. doi: 10.1038/ng0502-19. [DOI] [PubMed] [Google Scholar]
  • 34.O'Shaughnessy PJ, Fowler PA. Endocrinology of the mammalian fetal testis. Reproduction. 2011;141(1):37–46. doi: 10.1530/REP-10-0365. [DOI] [PubMed] [Google Scholar]
  • 35.Manna PR, Dyson MT, Stocco DM. Regulation of the steroidogenic acute regulatory protein gene expression: present and future perspectives. Molecular human reproduction. 2009;15(6):321–333. doi: 10.1093/molehr/gap025. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Lavoie HA, King SR. Transcriptional regulation of steroidogenic genes: STARD1, CYP11A1 and HSD3B. Experimental biology and medicine. 2009;234(8):880–907. doi: 10.3181/0903-MR-97. [DOI] [PubMed] [Google Scholar]
  • 37.Snyder EM, Small CL, Li Y, Griswold MD. Regulation of gene expression by estrogen and testosterone in the proximal mouse reproductive tract. Biology of reproduction. 2009;81(4):707–716. doi: 10.1095/biolreprod.109.079053. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Piprek RP. Molecular and cellular machinery of gonadal differentiation in mammals. Int J Dev Biol. 2010;54(5):779–786. doi: 10.1387/ijdb.092939rp. [DOI] [PubMed] [Google Scholar]
  • 39.Bowles J, Koopman P. Sex determination in mammalian germ cells: extrinsic versus intrinsic factors. Reproduction. 2010;139(6):943–958. doi: 10.1530/REP-10-0075. [DOI] [PubMed] [Google Scholar]
  • 40.Hermo L, Pelletier RM, Cyr DG, Smith CE. Surfing the wave, cycle, life history, and genes/proteins expressed by testicular germ cells. Part 1: background to spermatogenesis, spermatogonia, and spermatocytes. Microscopy research and technique. 2010;73(4):241–278. doi: 10.1002/jemt.20783. [DOI] [PubMed] [Google Scholar]
  • 41.Groudine M, Conkin KF. Chromatin structure and de novo methylation of sperm DNA: implications for activation of the paternal genome. Science. 1985;228(4703):1061–1068. doi: 10.1126/science.2986289. [DOI] [PubMed] [Google Scholar]
  • 42.Jenkins TG, Carrell DT. The sperm epigenome and potential implications for the developing embryo. Reproduction. 2012;143(6):727–734. doi: 10.1530/REP-11-0450. [DOI] [PubMed] [Google Scholar]
  • 43.Baarends WM, van der Laan R, Grootegoed JA. Specific aspects of the ubiquitin system in spermatogenesis. J Endocrinol Invest. 2000;23(9):597–604. doi: 10.1007/BF03343782. [DOI] [PubMed] [Google Scholar]
  • 44.Gerhart J. 1998 Warkany lecture: signaling pathways in development. Teratology. 1999;60(4):226–239. doi: 10.1002/(SICI)1096-9926(199910)60:4<226::AID-TERA7>3.0.CO;2-W. [DOI] [PubMed] [Google Scholar]
  • 45.Brennan J, Capel B. One tissue, two fates: molecular genetic events that underlie testis versus ovary development. Nat Rev Genet. 2004;5(7):509–521. doi: 10.1038/nrg1381. [DOI] [PubMed] [Google Scholar]
  • 46.Zhao GQ, Garbers DL. Male germ cell specification and differentiation. Dev Cell. 2002;2(5):537–547. doi: 10.1016/s1534-5807(02)00173-9. [DOI] [PubMed] [Google Scholar]
  • 47.Barsoum IB, Yao HH. Fetal Leydig cells: progenitor cell maintenance and differentiation. J Androl. 2010;31(1):11–15. doi: 10.2164/jandrol.109.008318. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Sanderson JT. The steroid hormone biosynthesis pathway as a target for endocrine-disrupting chemicals. Toxicol Sci. 2006;94(1):3–21. doi: 10.1093/toxsci/kfl051. [DOI] [PubMed] [Google Scholar]
  • 49.Rusyn I, Daston GP. Computational toxicology: realizing the promise of the toxicity testing in the 21st century. Environmental health perspectives. 2010;118(8):1047–1050. doi: 10.1289/ehp.1001925. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.The National Academies Press; 2007. NRC, Toxicity Testing in the 21st Century: A Vision and a Strategy. [Google Scholar]
  • 51.Judson RS, Kavlock RJ, Setzer RW, Cohen Hubal EA, Martin MT, Knudsen TB, et al. Estimating toxicity-related biological pathway altering doses for high-throughput chemical risk assessment. Chemical research in toxicology. 2011;24(4):451–462. doi: 10.1021/tx100428e. [DOI] [PubMed] [Google Scholar]
  • 52.Thomas RS, Clewell HJ, 3rd, Allen BC, Wesselkamper SC, Wang NC, Lambert JC, et al. Application of transcriptional benchmark dose values in quantitative cancer and noncancer risk assessment. Toxicological sciences : an official journal of the Society of Toxicology. 2011;120(1):194–205. doi: 10.1093/toxsci/kfq355. [DOI] [PubMed] [Google Scholar]
  • 53.Ankley GT, Bennett RS, Erickson RJ, Hoff DJ, Hornung MW, Johnson RD, et al. Adverse outcome pathways: a conceptual framework to support ecotoxicology research and risk assessment. Environ Toxicol Chem. 2010;29(3):730–741. doi: 10.1002/etc.34. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

1
2

RESOURCES